Elite PR joins Global Health Marketing & Communications (GHMC) as exclusive Taiwanese agency
Taiwan-based communications agency, Elite PR, has this week joined the world’s largest, and most robust network of independent healthcare agencies – Global Health Marketing & Communications (GHMC). Bolstering GHMC’s capabilities and footprint in the Asia Pacific (APAC) region, Elite PR has an exemplary, 35+ year-strong record of experience in the Taiwanese health sector. Established in…
VIVA! Communications welcomes new recruits
Today we have welcomed two new members to VIVA! Communications – PR Consultant Sophie Harrison and Account Executive, Sophie Ridley. Both Sophies will be charged with supporting the servicing of our VIVA! clientele, and further strengthening our agency’s health communications, digital and social expertise. Sophie H specialises in Sports Science and Public Health. She has…
TIME TO TALK ABOUT WOMEN’S HEARTS
Did you know that an estimated 1.2 million Australians are living with some form of cardiac, stroke or vascular disease. And that tragically, one woman loses their life every hour to heart disease – a disease which is 80 per cent preventable? Ischaemic Heart Disease (IHD) represented the second leading cause of death in Australian…
TIME TO SLIP, SLOP, SLAP, SEEK & SLIDE
On Saturday, December 9, 2023, Sydney sweltered through a heatwave that saw our airport reach 43.5 degrees Celsius – a December record. Sydney was not alone, with other NSW locations climbing beyond 40C that day. These high temperatures are set to continue, with experts calling for all Aussies to brace themselves for scorching temperatures up…
Aussies need a nationally consistent vaccination approach
Following a decline in vaccination rates following the peak of the COVID-19 pandemic, a new report is calling for a united, consistent, national approach to vaccinate Australians following a decline in vaccination rates after the peak of the COVID-19 pandemic. The Grattan Institute’s ‘A fair shot: How to close the vaccination gap’ report suggests taking…
Global Health Marketing and Communications (GHMC) welcomes Improve Comunicaciones as an exclusive agency partner in Mexico, strengthening network’s capabilities in Latin America
As the exclusive Australian partner of Global Health Marketing and Communications (GHMC) – the largest and most robust network of independent healthcare agencies worldwide – VIVA! Communications extends a warm welcome to our newest member – Improve Comunicaciones. The addition of the Mexican-based, strategic consulting agency to GHMC, strengthens our GHMC network’s offering, and capabilities…
New treatment now PBS listed for Australians living with chronic plaque psoriasis
The October 1, 2023 Pharmaceutical Benefits Scheme (PBS) listing of a new, once-daily, oral treatment for severe chronic plaque psoriasis represents good news for the estimated 19,000 Australian adults living with the common inflammatory skin disease. At VIVA! Communications, we are proud to be supporting the communication of this PBS listing announcement, working in partnership…
Happy International Women’s Day!
At VIVA! Communications, we believe in uplifting women and embracing equity in health + wellness. Today we are celebrating International Women’s Day (IWD) – a day that has symbolised the Women’s Rights movement since 1975. This IWD, we are focusing on achieving equitable access to healthcare and equity within the healthcare industry. Health systems and…
New Colombian comms partner strengthening our Global Health Marketing & Communications capabilities
To further strengthen our global network’s health communications expertise, Global Health Marketing & Communications (GHMC) today announced the addition of its newest member, Monodual Libera Ideas, a Colombian-based strategic communications, and consulting firm. GHMC is the world’s largest and most robust network of independent healthcare agencies, for which we – VIVA! Communications – have represented…
Tick of approval needed for Alzheimer’s disease medication in AUS
There are calls for the Therapeutic Goods Administration (TGA) to greenlight a breakthrough medication with the potential to slow the progression of Alzheimer’s disease. The Federal Drug Administration (FDA) recently approved humanised monoclonal antibody Lecanemab for use in patients with the neurodegenerative disease, in the wake of promising clinical trial outcomes. The medication, marketed as…